The week in industry: Nasal spray to treat depression gets FDA committee approval
This week: Moderna reports positive interim results from its Phase I vaccine study, Grey Wolf completes series A financing to secure US $14 million to develop immuno-oncology therapeutics and Charles River Laboratories continue to expand their early-stage CRO activity.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>